Trinity Biotech

Update in progress

TRIB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Trinity Biotech plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care sites across the Americas, Asia, Africa and Europe. Its portfolio includes infectious disease tests (SARS‑CoV‑2, EBV, measles, mumps, toxoplasmosis, CMV, rubella, varicella, others), HbA1c assays, autoimmune disease testing, and immunoassay platforms, plus reagents for liver and kidney diseases and anemia. It serves public health labs and clinical labs via direct sales and distributors, and collaborates on EpiCapture. Founded 1992, Bray, Ireland.

Company score

Sentiment: -0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.21; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.40; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.21; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive